16 results · 21ms · Sources: EU EUDAMED, US FDA

Get notified when this changes

We'll email you when new records match this search — new devices, new clearances, certificate changes, or withdrawals.

LORENZ RECONSTRUCTION SYSTEM WITH MODULAR SCREW

FDA 510(k)
FDA Class 2 ·Dental

Life Instruments

FDA UDI
Life Instrument Corporation·M930798051210·Stainless Frazier Suction 12FR 4.5" from bend

Life Instruments

FDA UDI
Life Instrument Corporation·M9307980512110·Custom Frazier w/holes 12Fr, 5" from 40° bend

AUTO/STAT KIT

FDA 510(k)
FDA Class 2 ·Clinical Chemistry

REVITALEYES, POST-SURGICAL SOFT DAILY WEAR CONTACT LENS (HIOXIFILCON B) CLEAR AND BLUE VISIBILITY TINT

FDA 510(k)
FDA Class 2 ·Ophthalmic

ARTICULEZE M HEAD 36MM +5 K980513

FDA Adverse Event
Injury ·DEPUY ORTHOPAEDICS INC US·Product code JDI·June 14, 2016

ZIMMER M/L TAPER FEMORAL STEM

FDA Adverse Event
Injury ·ZIMMER, INC.·Product code LPH·February 21, 2013

PRECISION TEST STRIPS

FDA Adverse Event
Malfunction ·ABBOTT DIABETES CARE, INC. USA·Product code NBW·February 7, 2011

POWERED WHEELCHAIR

FDA Adverse Event
Malfunction ·INVACARE TAYLOR STREET·Product code ITI·August 5, 2014

BD BACTEC¿ MYCO/F LYTIC CULTURE VIALS

FDA Adverse Event
Malfunction ·BECTON DICKINSON CARIBE LTD.·Product code MDB·March 20, 2023

BD BACTEC¿ MYCO/F LYTIC CULTURE VIALS

FDA Adverse Event
Malfunction ·BECTON DICKINSON CARIBE LTD.·Product code MDB·November 4, 2025

BD BACTEC¿ MYCO/F LYTIC CULTURE VIALS

FDA Adverse Event
Malfunction ·BECTON DICKINSON CARIBE LTD.·Product code MDB·January 11, 2023

BD BACTEC¿ MYCO/F LYTIC CULTURE VIALS

FDA Adverse Event
Malfunction ·BECTON DICKINSON CARIBE LTD.·Product code MDB·September 9, 2022

BD BACTEC¿ MYCO/F LYTIC CULTURE VIALS

FDA Adverse Event
Malfunction ·BECTON DICKINSON CARIBE LTD.·Product code MDB·July 8, 2022

BD BACTEC¿ MYCO/F LYTIC CULTURE VIALS

FDA Adverse Event
Malfunction ·BECTON DICKINSON CARIBE LTD.·Product code MDB·February 1, 2022

Animas(R) 2020 Insulin Infusion Pump Product Usage: This product is indicated for continuous subcutaneous infusion of insulin for the treatment of insulin-requiring diabetes.

FDA Enforcement
Class I ·Terminated·Animas Corporation·April 10, 2013